|1.115 -0.015 (-1.33%)||12-08 16:00|
|Targets||6-month :||2.9||1-year :||3.96|
|Resists||First :||2.48||Second :||3.39|
|Supports||First :||1.02||Second :||0.85|
|MAs||MA(5) :||1.22||MA(20) :||1.23|
|MA(100) :||2.74||MA(250) :||4.64|
|MACD||MACD :||-0.3||Signal :||-0.3|
|%K %D||K(14,3) :||11.1||D(3) :||20.3|
|52-week||High :||8.21||Low :||1.02|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MYNZ ] has closed above bottom band by 37.6%. Bollinger Bands are 59% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||1.21 - 1.22||1.22 - 1.22|
|Low:||1.05 - 1.06||1.06 - 1.07|
|Close:||1.1 - 1.11||1.11 - 1.12|
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Diagnostics & Research
|Shares Out||0 (M)|
|Shares Float||20 (M)|
|Held by Insiders||1.478e+007 (%)|
|Held by Institutions||23.7 (%)|
|Shares Short||110 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-3 %|
|Return on Assets (ttm)||104.9 %|
|Return on Equity (ttm)||-93.5 %|
|Qtrly Rev. Growth||874000 %|
|Gross Profit (p.s.)||127.1|
|Sales Per Share||-484.06|
|Qtrly Earnings Growth||-2 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-22 (M)|
|Price to Book value||0|
|Price to Sales||-0.01|
|Price to Cash Flow||3.66|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|